LOS ANGELES–(BUSINESS WIRE)–$BLUE #investors—The Law Offices of Frank R. Cruz announces an investigation of Bluebird Bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
In May 2020, in the midst of the COVID-19 pandemic, bluebird announced that the Company expected to submit a U.S. Biologics Licensing Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for LentiGlobin for sickle cell disease in the second half of 2021.
On November 4, 2020, post-market, bluebird disclosed that it would delay its BLA submission to late 2022 due to “feedback” from the FDA that requires the Company to provide additional data “to demonstrate drug product comparability” for LentiGlobin for sickle cell disease, as well as “COVID-19 related shifts and contract manufacturing organization COVID-19 impacts.”
On this news, bluebird’s stock price fell $9.72 per share, or 16.6%, to close at $48.83 per share on November 5, 2020.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased bluebird securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Powered by WPeMatico